Idorsia Aktie
| 3,92CHF | -0,04CHF | -0,89% |
WKN DE: A2DTEB / ISIN: CH0363463438
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
Bilanz (in Mio. CHF) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 1 077 | 596 | 276 | 255 | 0 |
| Summe Anlagevermögen | 405 | 308 | 224 | 250 | 0 |
| Summe Aktiva | 1 483 | 904 | 500 | 506 | 0 |
Bilanz (in Mio. CHF) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1 379 | 1 565 | 1 469 | 1 718 | 0 |
| Summe Eigenkapital | 104 | -661 | -969 | -1 212 | 0 |
| Summe Passiva | 1 483 | 904 | 500 | 506 | 0 |
Adresse
| Hegenheimermattweg 91, 4123 Allschwil | |
| Telefon | +41 (58) 844-10-10 |
| Internet | http://www.idorsia.com |
Management
|
Alberto Gimona
Head-Global Clinical Development & Executive VP |
|
Andrew Jones
SVP, Head-Corporate Communications & IR |
|
Antonio Olivieri
Chief Medical Officer & Head-Global Medical Affair |
|
Arno Groenewoud
Chief Financial Officer & Executive Vice President |
|
Bart Filius
Non-Executive Director |
|
Gaby Scherer
Senior VP & Head-Global Human Resources |
|
Jean-Paul Clozel
Chairman |
|
Julien Gander
Chief Legal & Corporate Development Officer, EVP |
|
Martine Clozel
Chief Scientific Officer, EVP & Head-Research |
|
Mathieu Simon
Vice Chairman |
|
Olivier Lambert
Senior Vice President & Head-Technical Operations |
|
Sandesh Mahatme
Non-Executive Director |
|
Srishti Gupta
Chief Executive Officer & Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.